scholarly journals Prevalence of Dyslipidemia and Goal Attainment with Lipid-Lowering Therapy: Insights from Thai Multicenter Study and Overview of the Major Guidelines

Dyslipidemia ◽  
2019 ◽  
Author(s):  
Songkwan Silaruks ◽  
Charn Sriratanasathavorn ◽  
Petch Rawdaree ◽  
Rapeephon Kunjara-Na-Ayudhaya ◽  
Bandit Thinkhamrop ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Goal Attainment ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy

Becoming more focused therapeutic lipid patterns: results from the Hungarian MULTI GAP 2010

2011 ◽  
Vol 152 (21) ◽  
pp. 822-827 ◽  
Author(s):  
István Reiber ◽  
György Paragh ◽  
László Márk ◽  
Gyula Pados
Keyword(s):  
High Risk ◽  
Goal Attainment ◽  
Treatment Strategies ◽  
Hdl Cholesterol ◽  
High Risk Group ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
Frequent Use ◽  
Risk Patients

Previous studies have found that many high-risk patients are not achieving their LDL-cholesterol goals, and many patients, despite being treated with lipid-lowering therapy, also have elevated triglycerides and/or low levels of HDL-cholesterol. Aims: Authors analyzed the treatment strategies for dyslipidemic subjects following cardiovascular events similarly to their former survey from 2008 and 2009. Methods: In the MULTI GAP (MULTI Goal Attainment Problem) 2010 trial data from standard and structured questionnaires of 2332 patients were processed. Authors analyzed the proportion of the patients reaching target levels for total cholesterol, LDL-C, HDL-C, A-C (atherogen cholesterol) and triglyceride. Results: 15% (n = 355) of the patients did not receive any lipid lowering treatment. 44% of the patients treated by specialists reached the target LDL-C level of 2.5 mmol/l. In „high risk” group target levels for HDL-C were reached by 61% of the patients, and for triglyceride by 43% of the subjects. 43% of the patients with the best compliance (>90%) reached the target LDL-C level of 2.5 mmol/l. Conclusion: There is a need for more effective lipid lowering therapy with more frequent use of higher doses of statins or combinations of lipid lowering drugs. Orv. Hetil., 2011, 152, 822–827.

scholarly journals LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China

Medicine ◽  
2017 ◽  
Vol 96 (46) ◽  
pp. e8555 ◽  
Author(s):  
Wen Zheng ◽  
Yu-Jiao Zhang ◽  
Xiang-Ting Bu ◽  
Xin-Zhu Guo ◽  
Da-Yi Hu ◽  
...  
Keyword(s):  
Northeast China ◽  
Goal Attainment ◽  
Ldl Cholesterol ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
Cholesterol Goal

Evaluation of Lipid-Lowering Therapy and Cholesterol Goal Attainment in Finland

2006 ◽  
Vol 6 (5) ◽  
pp. 349-355 ◽  
Author(s):  
Evo Alemao ◽  
Don Yin ◽  
Harri Sintonen ◽  
Veikko Salomaa ◽  
Pekka Jousilahti
Keyword(s):  
Goal Attainment ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
Cholesterol Goal

Correlates of LDL-cholesterol goal attainment in patients under lipid lowering therapy

2008 ◽  
Vol 199 (2) ◽  
pp. 368-377 ◽  
Author(s):  
Laurent Laforest ◽  
Philippe Moulin ◽  
Thierry Souchet ◽  
Cécile Ritleng ◽  
Gaëlle Desamericq ◽  
...  
Keyword(s):  
Goal Attainment ◽  
Ldl Cholesterol ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
Cholesterol Goal

Abstract 1244: Lipid Goals among Patients with Diabetes or the Metabolic Syndrome: The Lipid Treatment Assessment Project (L-TAP) 2

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
J W Jukema ◽  
Roger S Blumenthal ◽  
Raul D Santos ◽  
David D Waters ◽  
Michael Messig ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Goal Attainment ◽  
Fasting Glucose ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Success Rates ◽  
The Metabolic Syndrome ◽  
Lowering Therapy ◽  
Patients With Diabetes ◽  
Risk Patients

Background: Achievement of lipid targets is particularly important in individuals with diabetes mellitus (DM) and the metabolic syndrome (MS) because their cardiovascular (CV) risk is high. This analysis of the L-TAP 2 population compared goal attainment by DM status and number of MS components. Methods: In L-TAP 2, patients aged ≥20 years with dyslipidemia on stable lipid lowering therapy were assessed at investigation sites in 9 countries (US, Spain, Canada, Netherlands, Korea, France, Taiwan, Mexico, and Brazil) between September 2006 and April 2007. Lipid levels were determined once in each patient at time of enrollment. Achievement of LDL-C success (according to National Cholesterol Education Program Adult Treatment Panel III guidelines), triglycerides (TG) goals (<150 mg/dL), and HDL-C success (>40 mg/dL in men or >50 mg/dL in women) was compared using logistic regression by DM status and number of MS components (BMI ≥30 kg/m 2 , TG ≥150 mg/dL, HDL-C <40 mg/dL in men or <50 mg/dL in women, blood pressure ≥130/≥85 mm Hg, fasting glucose ≥110 mg/dL). Lipid and CRP levels were compared by DM status using ANOVA. Results: A total of 9955 patients were evaluated. Patients with DM, compared with those without DM, had significantly lower achievement of LDL-C success (67% vs 75%), TG goals (55% vs 64%), and HDL-C success (62% vs 75%; P <0.0001 for all comparisons). However, significantly more DM patients had LDL-C <70 mg/dL (28% vs 16%; P <0.0001). As the number of MS components increased, success rates significantly decreased for both LDL-C (81%, 75%, 71%, 69%, 69%, and 69% for 0, 1, 2, 3, 4, and 5 MS components respectively; P <0.0001) and HDL-C (91%, 74%, 50%, and 24% for 1, 2, 3, and 4 MS components respectively; P <0.0001). Patients with DM, compared with those without DM, had significantly higher CRP levels (1.86 vs 1.52 mg/L), significantly lower total cholesterol (175 vs 188 mg/dL), LDL-C (91 vs 104 mg/dL), HDL-C (49 vs 54 mg/dL), and non-HDL-C (125 vs 134 mg/dL), and higher TG (177 vs 155 mg/dL; P <0.0001 for all comparisons). Conclusions: This analysis indicates that despite their increased CV risk, patients with DM remain undertreated. Furthermore, as the number of MS components increases, lipid goal success rates decrease.

scholarly journals Akut coronariaszindróma miatt 2015-ben kezelt betegeink lipidcsökkentő terápiája

2018 ◽  
Vol 159 (12) ◽  
pp. 478-484
Author(s):  
László Márk ◽  
Mária Nagy ◽  
Győző Dani ◽  
Csaba Baranyai ◽  
Marianna Borbély ◽  
...  
Keyword(s):  
High Intensity ◽  
Goal Attainment ◽  
Cardiovascular Prevention ◽  
Coronary Intervention ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Coronary Syndrome ◽  
Medical Visits ◽  
Lowering Therapy ◽  
Significant Difference

Abstract: Introduction: The actual guidelines of cardiovascular prevention lay special emphasis on the lipid-lowering therapy of patients suffering from acute coronary syndrome (ACS). Aim: To evaluate the occurrence of high-intensity statin therapy, recommended by guidelines, at discharge in a Hungarian county hospital with hemodynamic laboratory in patients who underwent percutaneous intervention, furthermore the LDL-cholesterol (LDL-C) levels and goal attainment rate in the first year. Method: Retrospective data collection from the hospital database regarding the therapy at discharge and the lipid levels in the year following the intervention due to ACS in 2015. Results: Due to ACS event, 454 patients had coronary intervention in 2015, at discharge more than 90% of them received high-intensity statin (more than 80% rosuvastatin, 40 mg) or corresponding combination therapy. In 154 cases we found half-year lipid results; the median of LDL-C was 1.9 mmol/L, the 1.8 mmol/L target value attainment rate was 48.7%. Results after one year were found in 292 cases (73% without the deceased and foreign patients); the LDL-C median proved to be 2.0 mmol/L, the target level attainment rate was 37.3%. There was no significant difference between the results of patients from the three different ACS forms and between those of men and women. Conclusions: The lipid lowering therapy of the revascularized patients who come back for medical visits is acceptable, but greater emphasis has to be laid on increasing the rate of controlled patients compared to the present two-thirds. Orv Hetil. 2018; 159(12): 478–484.

Sign in / Sign up

Export Citation Format

Share Document